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Aims The activation of cannabinoid receptor type 2 (CB2)-mediated pathways might represent a promising anti-
atherosclerotic treatment. Here, we investigated the expression of the endocannabinoid system in human carotid
plaques and the impact of CB2 pharmacological activation on markers of plaque vulnerability in vivo and in vitro.
Methods
and results
The study was conducted using all available residual human carotid tissues (upstream and downstream the blood
flow) from our cohort of patients symptomatic (n ¼ 13) or asymptomatic (n ¼ 27) for ischaemic stroke. Intraplaque
levels of 2-arachidonoylglycerol, anandamide N-arachidonoylethanolamine, N-palmitoylethanolamine, N-oleoyletha-
nolamine, and their degrading enzymes (fatty acid amide hydrolase and monoacylglycerol lipase) were not different
in human plaque portions. In the majority of human samples, CB1 (both mRNA and protein levels) was undetectable.
In downstream symptomatic plaques, CB2 protein expression was reduced when compared with asymptomatic
patients. In these portions, CB2 levels were inversely correlated (r ¼ 20.4008, P ¼ 0.0170) with matrix metallopro-
tease (MMP)-9 content and positively (r ¼ 0.3997, P ¼ 0.0174) with collagen. In mouse plaques, CB2 co-localized
with neutrophils and MMP-9. Treatment with the selective CB2 agonist JWH-133 was associated with the reduction
in MMP-9 content in aortic root and carotid plaques. In vitro, pre-incubation with JWH-133 reduced tumour necrosis
factor (TNF)-a-mediated release of MMP-9. This effect was associated with the reduction in TNF-a-induced ERK1/2
phosphorylation in human neutrophils.
Conclusion Cannabinoid receptor type 2 receptor is down-regulated in unstable human carotid plaques. Since CB2 activation
prevents neutrophil release of MMP-9 in vivo and in vitro, this treatment strategy might selectively reduce carotid vul-
nerability in humans.
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Introduction
The endocannabinoid signalling system comprises two G--
protein-coupled receptors, the cannabinoid receptor type 1
(CB1) and 2 (CB2), the endogenous agonists at these receptors,
also known as endocannabinoids [the two most studied of which
are the lipids anandamide N-arachidonoylethanolamine (AEA)
and 2-arachidonoylglycerol (2-AG)], and enzymes for endocanna-
binoid biosynthesis and degradation.1 The endocannabinoid
system participates in a plethora of physiological and pathological
conditions. Its overall role, at the onset of nearly any type of cell
perturbation, is to be activated ‘on demand’ to help the cell, and
hence the organism, to re-establish the homeostasis to a level as
similar as possible to the one existing before that perturbation,
through the local regulation of the levels and activity of other
chemical signals, such as neurotransmitters, hormones, or cyto-
kines.1 A typical example of such role is represented by endocan-
nabinoid function in re-establishing energy homeostasis following a
brief period of food deprivation, mostly exerted via CB1 recep-
tors.2 Likewise, endocannabinoid signalling at CB2 receptors is
often triggered as a response to inflammation to either facilitate
or suppress immune cell function depending on whether or not
the inflammatory status is still beneficial.3 However, especially
during chronic pathological states, the endocannabinoid system
may become deranged and start contributing to the disorders ac-
companying hyperphagia, obesity, and inflammatory diseases, such
as atherosclerosis.4
Despite some controversies, early data pointed to CB2 and CB1
receptors as a protective and contributing factor, respectively, in
atherogenic inflammation.5,6 Here, we investigated the potential
role of the ‘intraplaque’ endocannabinoid system on local media-
tors of vulnerability, with emphasis on the CB2 putative control
of plaque levels of inflammatory cells, matrix metalloprotease
(MMP)-9, and collagen, in patients with severe carotid stenosis
(symptomatic or asymptomatic for ischaemic stroke), in a mouse
model of shear stress-induced atherogenesis and plaque vulnerabil-
ity in carotid artery and in vitro in neutrophils (a cell type particu-
larly infiltrating vulnerable plaques).7
Methods
For additional details, see Supplementary material online.
Patients and study design
All patients with available residual carotid tissues and previously en-
rolled in the unmatched case–control study (performed at San
Martino Hospital, Genoa, Italy) were included in the present substudy.7
Among the total cohort [81 patients with extracranial high-grade in-
ternal carotid stenosis (.70% luminal narrowing)8 and symptomatic
(n ¼ 18) or asymptomatic (n ¼ 63) for ischaemic stroke], biopsy ma-
terial was available for 13 symptomatic and 27 asymptomatic patients.
Patients were classified as symptomatic for ischaemic stroke after the
first episode of ipsilateral ischaemic stroke (focal neurological deficit of
acute onset lasting more than 24 h occurring between 30 and 10 days
prior to endarterectomy). Patients were defined as asymptomatic
when they had no history of ischaemic symptoms and in the absence
of signs of cerebral necrosis at magnetic resonance imaging with diffu-
sion sequences. Both asymptomatic and symptomatic patients under-
went carotid endarterectomy according to the recommendations
published by the Asymptomatic Carotid Surgery Trial (ACST), the
European Carotid Surgery Trial (ECST), and the North American
Symptomatic Carotid Endarterectomy Trial (NASCET).8 –10 The day
prior to endarterectomy, serum samples were obtained to measure
circulating markers of cardiovascular vulnerability. Medications
reported in Supplementary material online, Table S1, were not modi-
fied in the 2 months prior to enrolment. Exclusion criteria were: spon-
taneous cerebral embolism during 30 min preoperatively and during
the dissection phase of the operation, malignant hypertension, acute
coronary artery disease, any cardiac arrhythmias, congestive heart
failure (II, III, and IV NYHA classes), liver or renal disorder or function
abnormalities, acute and chronic infectious diseases, autoimmune and
rheumatic diseases, cancer, endocrine diseases, inflammatory bowel
diseases and anti-inflammatory (other than aspirin) medications, oral
anticoagulant treatments, and hormone, cytokine, or growth factor
therapies.
The Medical Ethics Committee of San Martino Hospital approved
the study and participants provided written informed consent. The
study was conducted in compliance with the Declaration of Helsinki.
Human carotid plaque specimen processing
Shortly after surgical excision, the internal carotid plaque specimens
were cut perpendicularly to the long axis through the point of
maximum stenosis to obtain two portions (upstream and downstream
of the blood flow; see Supplementary material online, Figure S1A).7
Each portion was further divided perpendicularly to the long axis in
the middle into two subsegments. One half was snap-frozen in liquid
nitrogen and stored at 2808C (for mRNA isolation and endocannabi-
noid measurements), and the other half was frozen in cryoembedding
medium for histological analysis (see Supplementary material online,
Figure S2A).
Mouse model of shear stress-induced
atherogenesis and plaque vulnerability
Apolipoprotein E-deficient mice (apoE2/2) in a C57BL/6J background
were obtained from The Charles River Laboratories. Animals at 15–20
weeks of age were randomly assigned to receive either vehicle (n ¼ 6)
or the selective CB2 agonist JWH-133 (n ¼ 7) treatment. During the
experimental period, all animals were fed a Western-type diet consist-
ing of 15% (wt/wt) cocoa butter and 0.25% (wt/wt) cholesterol (Diet
W; abDiets). After a 2-week period of Western diet, shear stress in
the right common carotid artery was altered by cast surgical place-
ment.11 This model was reported in detail in the Supplementary mater-
ial online. Nine weeks after surgery, the animals were euthanized to
collect tissue and serum samples. During the last 3 weeks before eu-
thanizing (from Weeks 6 to 9 of cast implantation), mice were intra-
peritoneally injected with the selective CB2 agonist JWH-133 (5 mg/
kg/day for 5 consecutive days per week, Tocris Bioscience, Bristol,
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UK) or respective vehicle control (TocrisolveTM 100, Tocris Bio-
science). In selective experiments, to assess the CB2 levels in mouse
carotid and aortic root plaques, animals (n ¼ 4) were intraperitoneally
and daily injected with phosphate-buffered saline (PBS) (for 5 consecu-
tive days per week from Weeks 6 to 9 with cast). This animal study
was approved by local Ethics Committee and Swiss authorities and
conformed to the ‘position of the American Heart Association on Re-
search Animal Use’.
Immunohistochemistry in human carotid
plaques, mouse carotid plaques, and mouse
aortic sinus
Frozen upstream and downstream human carotid specimens, mouse
carotid arteries, and aortic sinus were serially cut and stained as
described in the Supplementary material online.
Oil Red O staining for lipid content
Oil Red O staining was performed as described in the Supplementary
material online.
Sirius red staining for collagen content
Sirius red staining was performed as described in detail in the Supple-
mentary material online.
Real-time RT–PCR
Real-time PCR was performed as described in detail in the Supplemen-
tary material online. Specific primers and probes were used to deter-
mine the mRNA expression of CNR1 (CB1 receptor), fatty acid amide
hydrolase, monoacylglycerol lipase, matrix metalloproteinase-8
(MMP-8), and GAPDH (housekeeping gene) and are reported in the
Supplementary material online, Table S3.
Quantification of endocannabinoids
After lipid extraction and pre-purification, endocannabinoid fractions
were assessed as described in detail in the Supplementary material
online.
Human primary neutrophil isolation and
culture
Human neutrophils, obtained from healthy volunteers after informed
consent, were isolated and cultured as described in detail in the Sup-
plementary material online.
Apoptosis assay
Apoptosis rates of neutrophils after 2 h of treatment with JWH-133
(1 mM) and AM630 (1 mM) were determined via the analysis of phos-
phatidylserine externalization using an annexin V-FITC apoptosis de-
tection kit (Medical and Biological Laboratories Co., Ltd, Woburn,
MA, USA).
Flow cytometry
Flow cytometry on human neutrophils was assessed as described in
detain in the Supplementary material online.
Detection of inflammatory mediators in
human serum and cell supernatants
Inflammatory markers were assessed in human serum and cell super-
natants as described in detail in the Supplementary material online.
Pro-matrix metalloprotease-9 zymographic
assay
Pro-matrix metalloprotease-9 zymographic activity was assessed in
human serum and cell supernatants as described in detail in the Sup-
plementary material online.
Western blot analysis
Western blot on human neutrophils were performed as described in
detail in the Supplementary material online.
Statistical analysis
Patient characteristics were described 1 day before endarterectomy.
Patients asymptomatic for ischaemic stroke were compared with
symptomatic patients using Pearson’s x2 test or Fisher’s exact test
(when appropriate) for the comparison of qualitative variables. The
Mann–Whitney non-parametric test (the normality assumption of
the variables’ distribution in both groups was violated) was used for
comparisons of continuous variables. Comparisons between para-
meters of mouse plaque vulnerability in JWH-133- and vehicle-treated
mice were performed using the Mann–Whitney test. For continuous
variables, results were expressed as medians [inter-quartile range
(IQR)]. Spearman’s rank correlation coefficients were used to assess
correlations between CB2 levels and, respectively, intraplaque con-
tents of lipids, collagen, vascular and inflammatory cells, MMP-9, or
MMP-8 mRNA expression (DCT) in both upstream and downstream
regions of carotid atherosclerotic plaques. In vitro results were
expressed as means (+SD) (ERK phosphorylation in human neutro-
phils) and as medians (IQR) (neutrophil release of MMP-9 and
zymography). One-way ANOVA was used for multiple group compari-
son, and the unpaired Student t-test was used for two-group compari-
son. Values of P, 0.05 (two-tailed) were considered significant. All
analyses were done with StatisticaTM software (StatSoft, Tulsa, OK,
USA).
Results
Patient characteristics and systemic levels
of cardiovascular risk biomarkers
Based on the criterion of the residual availability of carotid plaque
samples for measuring the mediators of the endocannabinoid
system, we included in the present substudy 27 patients asymptom-
atic and 13 symptomatic for ischaemic stroke. Their clinical and bio-
logical characteristics, as well as medications, are reported in
Supplementary material online, Table S1. No significant difference
between asymptomatic and symptomatic in terms of age, sex, co-
morbidities, laboratory parameters, and medications was found.
Then, we focused on serum inflammatory cardiovascular risk bio-
markers, recently suggested to be potentially useful in the assess-
ment of the global cardiovascular vulnerability.12 Patients
symptomatic for ischaemic stroke had increased serum levels of
MMP-8 when compared with the asymptomatic group (see Supple-
mentary material online, Table S4). No significant differences in the
serum levels of MMP-9 and their tissue inhibitors were observed
between the two groups (see Supplementary material online,
Table S4).
F. Montecucco et al.848
Intraplaque levels of cannabinoid
receptor type 2 receptor are reduced in
downstream portions of symptomatic
plaques and inversely associated with
parameters of vulnerability
The levels of mediators of the endocannabinoid system and plaque
vulnerability were investigated in the upstream and downstream
portions of human carotid plaques. In agreement with our previ-
ously published data from the entire cohort,7 upstream portions
of symptomatic plaques had increased lipid, neutrophil, and
MMP-9 contents when compared with corresponding regions in
asymptomatic patients (Table 1 and Figure 1A–C). On the other
hand, collagen and smooth muscle cell contents were decreased
in the symptomatic upstream portion when compared with asymp-
tomatic (Table 1 and Figure 1D and E). No significant differences
between the symptomatic and asymptomatic groups in macro-
phage infiltration, MMP-8 mRNA expression, as well as in all endo-
cannabinoid system components were found in upstream plaque
regions (Figure 1F and Table 1). In downstream portions of
carotid plaques, intraplaque neutrophil and MMP-9 contents
were significantly increased in symptomatic patients when com-
pared with asymptomatic (Table 1 and Figure 2B and C). According-
ly, collagen content was decreased in symptomatic patients when
compared with asymptomatic (Table 1 and Figure 2D). Interestingly,
intraplaque levels of CB2 were strongly reduced in downstream
portions of symptomatic patients when compared with asymptom-
atic (Table 1 and Figure 3). No significant differences were observed
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Table 1 Parameters of intraplaque vulnerability
Carotid intraplaque parameters Asymptomatic (n5 27) Symptomatic (n5 13) P-value vs. asymptomatic
Upstream portion
% lipid 7.0 (4.0–9.0) 9.4 (7.9–14.8) 0.005
% total collagen 25.2 (18.4–33.3) 14.2 (9.3–17.4) 0.0008
% collagen I 13.3 (10.2–16.4) 5.5(3.3–8.1) 0.0003
% collagen III 12.9 (9.3–18.3) 7.0 (5.4–8.2) 0.0002
% of smooth muscle cell-rich area 7.9 (4.5–10.3) 3.3 (5.6–2.4) 0.004
% of macrophage-rich area 5.7 (2.8–10.3) 7.4 (6.3–9.3) 0.15
Neutrophils/mm2 2.4 (1.0–2.7) 5.4 (4.3–7.5) 0.0006
MMP-8 mRNA, fold increase 0.46 (0.22–1.20) 0.49 (0.12–1.05) 0.60
% MMP-9 4.0 (2.0–5.3) 11.1 (7.4–13.2) 0.005
% CB2 receptor-rich area 1.7 (0.3–3.0) 1.5 (0.1–2.4) 0.48
MAGL mRNA, fold increase 0.84 (0.64–1.08) 0.80 (0.73–0.87) 0.54
FAAH mRNA, fold increase 0.69 (0.46–1.12) 0.52 (0.30–0.95) 0.20
AEA, pmol/g 38.5 (26.8–52.9) 39.7 (29.9–50.9) 0.87
2-AG, pmol/mg 0.70 (0.46–1.03) 0.89 (0.61–1.31) 0.36
PEA, pmol/mg 0.21 (0.16–0.39) 0.24 (0.18–0.46) 0.76
OEA, pmol/mg 0.12 (0.09–0.21) 0.18 (0.16–0.26) 0.17
Downstream portion
% lipid 2.7 (1.5–4.4) 3.3 (2.2–5.9) 0.47
% total collagen 18.8 (10.3–24.4) 11.3 (10.3–13.3) 0.05
% collagen I 10.8 (5.5–12.9) 5.5 (5.3–7.5) 0.02
% collagen III 9.1 (4.6–11.7) 5.8 (3.4–6.4) 0.04
% of smooth muscle cell-rich area 3.3 (2.0–5.5) 2.3 (1.8–3.2) 0.06
% of macrophage-rich area 7.1 (2.3–17.5) 15.3 (6.3–17.5) 0.32
Neutrophils/mm2 6.1 (1.8–11.9) 11.6 (10.2–15.3) 0.005
MMP-8 mRNA, fold increase 0.62 (0.20–1.50) 0.60 (0.07–1.55) 0.49
% MMP-9 5.3 (2.8–8.0) 10.3 (7.4–19.9) 0.01
% CB2 receptor-rich area 1.3 (0.6–5.0) 0.2 (0.01–1.1) 0.01
MAGL mRNA, fold increase 0.76 (0.58–0.97) 0.64 (0.56–0.81) 0.36
FAAH mRNA, fold increase 0.40 (0.25–0.80) 0.30 (0.23–0.67) 0.48
AEA, pmol/g 32.3 (23.8–54.8) 37.3 (27.2–48.2) 0.78
2-AG, pmol/mg 0.73 (0.52–10.2) 0.95 (0.74–1.23) 0.18
PEA, pmol/mg 0.32 (0.22–0.44) 0.32 (0.27–0.38) 0.87
OEA, pmol/mg 0.21 (0.13–0.30) 0.25 (0.18–0.27) 0.35
Data are expressed as median (inter-quartile range). CB, cannabinoid; MAGL, monoacylglycerol lipase; FAAH, fatty acid amide hydrolase; AEA, anandamide; 2-AG,
2-arachidonoylglycerol; PEA, N-palmitoylethanolamine; OEA, N-oleoylethanolamine.
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in the expression of other intraplaque parameters, MMP-8 mRNA
expression, endocannabinoids (AEA or 2-AG), or
endocannabinoid-like molecules [N-oleoylethanolamine (OEA)
and N-palmitoylethanolamine (PEA)] (Table 1). In human carotid
plaque samples, CB1 content was almost undetectable at both
mRNA {detectable in 13 asymptomatic and 5 symptomatic up-
stream plaques [median (IQR) of fold increase in upstream
plaque, respectively: 0.94 (0.52–0.34) vs. 0.24 (0.23–1.19), P ¼
0.37]; detectable in 15 asymptomatic and 3 symptomatic down-
stream plaques [median (IQR) of fold increase in asymptomatic up-
stream, respectively: 0.49 (0.28–0.92) vs. 0.29 (0.21–0.41), P ¼
0.17]} and protein levels (detectable in 3 asymptomatic and 1
symptomatic patients, data not shown). In downstream portions,
CB2 content was positively correlated with protective intraplaque
collagen
(r ¼ 0.3997, P ¼ 0.0174) and inversely with MMP-9 content (r ¼
20.4008, P ¼ 0.0170) (see Supplementary material online, Table
S5). No significant correlations were observed between intrapla-
que CB2 levels and other parameters of plaque vulnerability (see
Supplementary material online, Table S5). By confirming that
human carotid plaques are highly heterogeneous tissues,7 these
results indicate that intraplaque levels of CB2 receptor are
reduced in the most vulnerable regions where MMP-9 is increased
and collagen is reduced.
Treatment with selective cannabinoid
receptor type 2 agonist JWH-133 reduces
matrix metalloprotease-9 content in
atherosclerotic plaques in ApoE2/2 mice
We first investigated the expression of CB2 in atherosclerotic
vessels in a mouse model of shear stress-induced atherogenesis
and plaque vulnerability.11 This experiment was done in mice
treated with PBS (control) to be next to disease pathophysiology
and avoid any artifact potentially induced by the vehicle (Tocri-
solve). Cannabinoid receptor type 2 protein expression was
higher in carotid arteries when compared with aortic roots
(Figure 4A–C ). In plaques from mouse aortic roots, CB2 particular-
ly co-localized with both neutrophils and MMP-9-rich areas
(Figure 4C). Only partial co-localization was observed between
CB2 and macrophages (Figure 4C). Then, the potential protective
effect of selective CB2 pharmacological activation was assessed in
mice treated with JWH-133 or the corresponding vehicle (Tocri-
solve) for the last 3 weeks (6 weeks after the cast placement)
before analysing. Intraplaque vulnerability was assessed in the
Figure 1 Parameters of plaque vulnerability in upstream por-
tions of carotid plaques. Representative sections from human
asymptomatic and symptomatic carotid plaques showing staining
for lipids (A), neutrophils (B), matrix metalloprotease-9 (C), col-
lagen (D), smooth muscle cells (E), and macrophages (F ). Colla-
gen specificity is shown under bright illumination without
polarization (upper part of panel D) and under polarized light il-
lumination (lower part of panel D).
Figure 2 Parameters of plaque vulnerability in downstream
portions of carotid plaques. Representative sections from
human asymptomatic and symptomatic carotid plaques showing
staining for lipids (A), neutrophils (B), matrix metalloprotease-9
(C), collagen (D), smooth muscle cells (E), and macrophages
(F). Collagen specificity is shown under bright illumination
without polarization (upper part of panel D) and under polarized
light illumination (lower part of panel D).
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aortic roots and in the different shear stress regions of carotid
artery [low shear stress (LSS) and oscillatory shear stress (OSS)].
At sacrifice, mouse body weight, serum total cholesterol, and tri-
glycerides were similar in the two experimental groups (see Sup-
plementary material online, Table S6). In LSS carotid plaques,
JWH-133 treatment did not induce any change in relative plaque
content of lipids, macrophages, neutrophils, collagen, and MMP-9
(Table 2; see Supplementary material online, Figures S3A–C and
S4A and B). Similarly, no difference was observed in lipid content
and macrophage infiltration in OSS carotid and aortic root
plaques (Table 2; see Supplementary material online, Figure S3A
and B). However, neutrophil infiltration was reduced in aortic
root plaques of JWH-133-treated mice when compared with con-
trols (Table 2; see Supplementary material online, Figure S3C). No
significant difference in intraplaque collagen content was shown
between JWH-133 and control-treated mice (Table 2; see Supple-
mentary material online, Figure S4A). Conversely, JWH-133 treat-
ment was associated with lower MMP-9 plaque content in both
OSS carotid and aortic root plaques (Table 2; see Supplementary
material online, Figure S4B). These results indicate that in vivo
CB2 activation with the selective agonist JWH-133 was associated
with a weak reduction in MMP-9 content in mouse plaques consid-
ered more stable.11
Cannabinoid receptor type 2 activation
reduces tumour necrosis
factor-a-mediated release of matrix
metalloprotease-9 in human primary
neutrophils
To investigate whether the activation of CB2 cannabinoid recep-
tors might interfere with the release of MMP-9 by cells infiltrating
carotid plaques,7 we performed in vitro cultures of human neutro-
phils. We tested the potential benefits of CB2 activation on cells
adherent to polystyrene dishes and stimulated with tumour necro-
sis factor (TNF)-a (a pro-atherosclerotic cytokine previously
shown to induce MMP-9 release by human neutrophils).13 Stimula-
tion with 100 ng/mL TNF-a induced the release of MMP-9 by
human neutrophils in a comparable manner to the positive
control phorbol-12-myristate-13-acetate (PMA) (Figure 5A). Pre-
incubation with the selective CB2 receptor agonist JWH-133 (at
0.3 and 1 mM) significantly reduced TNF-a-mediated release of
MMP-9 by human neutrophils (Figure 5A). JWH-133-induced bene-
fits were partially reversed by co-incubation with the selective CB2
antagonist AM630 (Figure 5A). No effects were induced by the in-
cubation with the CB2 agonist or antagonist in the absence of
TNF-a. Similar results were observed by assessing pro-MMP-9
Figure 3 Cannabinoid receptor type 2 expression is reduced in downstream portions of symptomatic plaques. Representative sections from
human carotid plaques showing staining for cannabinoid receptor type 2.
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gelatinolytic activity in neutrophil supernatants (Figure 5B and C).
Cell viability in the presence of JWH-133 or AM630 was also
assessed in the cell cultures by flow cytometric analysis of
annexin V-FITC and propidium iodide staining. Pre-treatment
with the cannabinoid agonist/antagonist did not induce any
effects on early apoptosis, nor late apoptosis/necrosis (data not
shown). We further investigated the potential molecular mechan-
ism(s) underlying the beneficial effects of CB2 activation on
TNF-a-mediated release of MMP-9, focusing on the membrane
surface expression of TNF receptors and their downstream intra-
cellular kinase pathways. Treatment for 2 h with different concen-
trations of JWH-133 did not induce any effect on TNFRI and
TNFRII expression when compared with control medium alone
(see Supplementary material online, Figure S5A and B). Given the
potential role for ERK1/2 in TNF-a-mediated degranulation of
MMP-9,13 we investigated whether CB2 pre-activation could
modulate this pathway. Pre-incubation with PD98059 (selective in-
hibitor of MEK, a kinase directly activating ERK1/2) at 25 mM
Figure 4 Cannabinoid receptor type 2 is expressed in mouse carotid and aortic root plaques. (A) Cannabinoid receptor type 2 protein ex-
pression in low shear stress, high shear stress (HSS), oscillatory shear stress carotid and aortic root plaques of phosphate-buffered saline-
treated mice (n ¼ 4). Data are expressed as median (inter-quartile range). (B) Representative microphotographs of CB2 staining in mouse
carotid plaques in low shear stress, HSS, and oscillatory shear stress carotid portions. (C) Representative microphotographs of consecutive
cryosections from root plaques of phosphate-buffered saline-treated mice for, respectively, CB2, macrophages (CD68
+ cells), neutrophils
(Ly-6B.2+ cells), and matrix metalloprotease-9.
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abrogated the increase in MMP-9 release and activity mediated by
TNF-a (see Supplementary material online, Figure S6A–C). To
confirm these findings, we directly assessed the effects of CB2 ac-
tivation on ERK1/2 phosphorylation. Pre-treatment with 0.3–1 mM
JWH-133 was associated with a strong reduction in ERK1/2 phos-
phorylation in response to TNF-a (Figure 6A and B), indicating that
this intracellular pathway is crucial for CB2-mediated beneficial ac-
tivity on the neutrophilic response to TNF-a.
Discussion
Human study
Our study shows that the expression of the CB2 receptor protein
is markedly reduced in carotid plaque portions downstream the
blood flow in patients symptomatic for ischaemic stroke when
compared with asymptomatic ones. In the same plaque regions,
CB2 protein expression inversely correlated with MMP-9 expres-
sion and directly with collagen content (recognized parameters
of plaque vulnerability).7,12 These data suggest that CB2 might be
down-regulated in the most vulnerable portions of symptomatic
plaques. Given these differences between intraplaque parameters
in regions upstream or downstream the blood flow, we also con-
firmed that the high heterogeneity of carotid plaque tissues might
be crucially influenced by the mechanical shear stress.7,11,14
Differently from Sugamura et al.15 who showed that CB1 is
highly expressed in human coronary plaques, very little and
hardly detectable amounts of protein or mRNA of CB1 receptor
were retrieved in our human carotid plaque samples. This unex-
pected result was obtained in both symptomatic and asymptomatic
patients. Furthermore, no changes in the local levels of the two
major endocannabinoids (anandamide and 2-AG) and two en-
dogenous peroxisome proliferator-activated receptor-a ligands
(OEA and PEA)16 were observed between symptomatic and
asymptomatic patients, despite them being well above detection
limits, and even reaching concentrations potentially effective at
cannabinoid receptors (particularly for 2-AG, the concentration
of which ranged between 0.73 and 0.95 mM). Our findings were
not explained by a lack of power due the largest sample sizes
used in our study compared with those of Sugamura et al.15 On
the other hand, these results might suggest that unlike coronary
atheromas, the endocannabinoid tone in carotid plaques might
uniquely reduce plaque vulnerability via CB2 receptor activation
and does not also participate in plaque formation via CB1 recep-
tors. Therefore, when CB2 receptor expression is decreased, as
we have observed here in carotid plaques from symptomatic
patients, this might contribute to the increase in vulnerability via
uncontrolled release of MMP-9 and subsequent collagen
degradation.
Animal study
We have provided evidence suggesting that intraplaque cannabin-
oid CB2 receptor activation, for which previous data indicate a pro-
tective role against atherosclerotic plaque formation,5,6,17 may also
decrease the vulnerability of carotid plaques by reducing MMP-9
release. Since this protease has been indicated as a parameter asso-
ciated with the ‘cannibal’ intraplaque collagen degradation,18 the
potential involvement of the CB2 pathway in MMP-9 regulatory
mechanisms might have a pathophysiological relevance. In order
to assess the potential benefits of a pharmacological approach
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Table 2 Parameters of mouse plaque vulnerability
Parameters Vehicle-treated mice (n 5 6) JWH-133-treated mice (n 5 7) P-value
Carotid LSS
Oil-red-O, ×103 mm2 179.5 (24.7–198.0) 22.1 (15.4–49.2) 0.18
Macrophage+ area, % 5.1 (0.1–8.7) 0.6 (0.1–2.4) 0.42
Neutrophils/mm2 1.7 (0.02–4.5) 0.06 (0.04–0.19) 0.52
Total collagen, % 18.1 (17.7–26.7) 12.9 (7.0–15.2) 0.05
MMP-9, % 1.6 (0.4–2.8) 0.09 (0.05–1.11) 0.17
Carotid OSS
Oil-red-O, ×103 mm2 155.3 (101.0–163.5) 179.8 (148.9–212.2) 0.37
Macrophage+ area, % 2.6 (0.6–7.4) 3.6 (1.3–5.5) 0.68
Neutrophils/mm2 1.3 (0.5–3.2) 0.65 (0.1–1.4) 0.22
Total collagen, % 10.4 (9.6–12.9) 15.2 (10.9–20.5) 0.17
MMP-9, % 3.9 (0.5–6.8) 0.4 (0.2–1.5) 0.04
Aortic roots
Oil-red-O, ×103 mm2 172.2 (140.0–203.2) 223.6 (161.2–239.3) 0.10
Macrophage+ area, % 17.3 (15.0–20.2) 18.9 (13.4–19.3) 0.94
Neutrophils/mm2 7.2 (4.7–18.2) 2.4 (2.0–19.3) 0.01
Total collagen, % 33.0 (18.4–40.0) 39.3 (33.7–55.6) 0.07
MMP-9, % 6.0 (4.3–11.9) 1.9 (1.6–2.3) 0.001
Data are expressed as median (inter-quartile range). MMP, matrix metalloproteinase.
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activating CB2 to reduce plaque vulnerability, we used a mouse
model of shear stress-induced atherogenesis and plaque vulnerabil-
ity. We observed a weak but significant reduction in MMP-9 intra-
plaque levels (aortic roots and OSS carotid portions) in animals
treated with the selective CB2 agonist JWH-133 when compared
with the control vehicle. Extrapolated to humans, these mouse
results may suggest a causal relationship between CB2 activity
and reduced MMP-9 release.
In vitro study
In order to identify the intraplaque source of MMP-9, we studied
the localization of this metalloproteinase in consecutive sections
of mouse plaques and observed its co-occurrence with CB2 in
Figure 5 Pre-treatment with JWH-133 reduces tumour necro-
sis factor-a-mediated exocytosis of matrix metalloprotease-9 by
human neutrophils. Matrix metalloprotease-9 release and activity
in supernatants of cells incubated in polystyrene dishes in the pres-
ence or absence (30 min at 378C) of control medium (CTL), 10 ng/
mL phorbol-12-myristate-13-acetate (PMA, positive control),
100 ng/mL tumour necrosis factor-a, 1 mM JWH-133 (JWH), and
1 mM AM630 (AM). In selective experiments (right part of the his-
tograms and gel), tumour necrosis factor-a stimulation was pre-
ceded by 2 h incubation with different doses of JWH-133 (JWH)
and 1 mM AM630 (AM). Data are expressed as median (inter-
quartile range). (A) Matrix metalloprotease-9 release (n ¼ 7). (B)
Representative gel of matrix metalloprotease-9 zymography.
White band (arrow) on the gel represents the pro-matrix
metalloprotease-9 gelatinolytic activity of standard recombinant
pro-matrix metalloprotease-9 (ST), and supernatants of cells. (C)
Results of densitometric quantifications of seven different zymo-
graphy experiments.
Figure 6 Pre-treatment with the CB2 receptor agonist
JWH-133 reduces tumour necrosis factor-a-mediated phosphor-
ylation of ERK1/2 in human neutrophils. Neutrophils were pre-
incubated for 2 h at 378C in the presence or absence of different
concentrations of JWH-133 (JWH). Then, without washing, cells
were further stimulated for 7 min at 378C in the presence or
absence of control medium (CTL), cannabinoid vehicle (V),
1 mM JWH-133 (JWH), or 100 ng/mL tumour necrosis
factor-a. (A) Representative western blot analysis of ERK1/2
phosphorylation. (B) Densitometric analysis of phospho-ERK1/2
(P-ERK1/2). Values were, respectively, normalized to amounts
of total ERK1/2 and expressed as percentage of control
medium (CTL), defined as 100%. Data are expressed as
mean+ SD (n ¼ 3).
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infiltrating neutrophils. Since neutrophils have been detected par-
ticularly in human unstable plaques7 and indicated as a potent pro-
ducer of MMP-9 in response to pro-atherosclerotic cytokines
(such as TNF-a),13 we envisaged that these cells might be the po-
tential cellular target of the CB2-mediated beneficial stimulation.
Results showed that pre-incubation with JWH-133 dose-
dependently reduced the neutrophilic release of MMP-9 in re-
sponse to TNF-a. Intriguingly, selective CB2 activation did not
interfere with the surface expression of TNF receptors, but abro-
gated the phosphorylation of one of the most important inflamma-
tory intracellular pathways (i.e. ERK1/2), activated by TNF-a.19 Via
the activation of this kinase, TNF-a has been shown to induce
several pro-atherosclerotic functions in inflammatory cells.20
However, ERK1/2 phosphorylation has not been shown before
to be responsible for the MMP-9 release by human neutrophils.13
Taking into account our results using different doses of the select-
ive ERK1/2 pathway inhibitor (PD98059) and showing that
TNF-a-mediated ERK1/2 phosphorylation preceded MMP-9
release (7 vs. 30 min), we conclude that this intracellular
pathway might be also involved in the deleterious neutrophilic
release of MMP-9. These findings provide a cellular and molecular
mechanism to the previously described enhancement of MMP-9
up-regulation in double low-density lipoprotein receptor (ldlr)
and CB2 knockout mice, in the absence of any net effect on athero-
sclerotic plaque formation.5 Together with this previous report,
our data suggest that systemic administration of selective CB2 re-
ceptor agonists might perhaps be used as an atherosclerotic
plaque pacifier agent in patients with significant but asymptomatic
carotid stenosis.
Limitations and conclusions
The present ‘translational’ study has some limitations. The study in
humans is mainly an observational study comparing samples col-
lected after the ischaemic event. Thus, we cannot establish
whether CB2 reduction in symptomatic downstream plaque is
the cause or the effect consequence of a potential plaque
rupture. In addition, since the study was not designed as prospect-
ive, we cannot also estimate the potential association between CB2
expression and the risk of stroke recurrence. Finally, as the number
of subjects in human and mouse studies are low, our conclusions
require the confirmation on larger studies. Nonetheless, the
study sample size allowed us to show a large difference of 1.6, con-
sidered as clinically relevant, on the intraplaque cannabinoid recep-
tor expression between symptomatic and asymptomatic patients.15
In conclusion, our data suggest that CB2 activation rather than
CB1 inhibition should be considered to abrogate the intraplaque
neutrophilic release of MMP-9. Although the role of CB2 receptors
as atherogenic modulators in mice remains marginal and therefore
controversial and the benefits associated with the treatment with
the selective CB2 agonist JWH-133 were weak in atherosclerotic
mice,5,21 our translational results indicate that a treatment strategy
targeting CB2 activation might be effective in human beings. There-
fore, the selective activation of the CB2 pathway (possibly without
interfering with endocannabinoid signalling in the brain) might be
appealing as a therapeutic approach for clinical studies to combat
atherosclerotic plaque vulnerability through the reduction in
MMP-9 neutrophilic degranulation.
Supplementary material
Supplementary material is available at European Heart Journal
online.
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